CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...